Benign prostatic hyperplasia in primary care: What you need to know

被引:48
|
作者
Burnett, AL
Wein, AJ
机构
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[2] Univ Penn, Hlth Syst, Philadelphia, PA 19104 USA
来源
JOURNAL OF UROLOGY | 2006年 / 175卷 / 03期
关键词
prostate; benign prostatic hyperplasia; bladder neck obstruction; urination disorders;
D O I
10.1016/S0022-5347(05)00310-1
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We reviewed recent literature and treatment guidelines regarding the prevalence, pathophysiology, and management of BPO related to BPH; and management of lower urinary tract symptoms secondary to BPH. Materials and Methods: Published literature and current treatment concepts were reviewed regarding the diagnosis and treatment options for BPO. Results: BPH is a histological diagnosis that can contribute to medical problems, including enlargement of the prostate and BPO. These conditions should be treated only if the symptoms are troublesome, there is considerable risk of progression, and/or cancer is suspected. Very effective medical and surgical options are available to treat BPO and improve patient quality of life. Conclusions: BPO is highly treatable, but should be managed in close collaboration with the patient. Pharmacological agents and minimally invasive procedures, when appropriate, are generally preferred to more invasive surgery. Patients with mild or moderate symptoms usually can be treated by a primary care physician; more complicated cases should be referred to a urologist for evaluation and management.
引用
收藏
页码:S19 / S24
页数:6
相关论文
共 50 条
  • [1] Benign prostatic hyperplasia - what do we know?
    Devlin, Conor M.
    Simms, Matthew S.
    Maitland, Norman J.
    BJU INTERNATIONAL, 2021, 127 (04) : 389 - 399
  • [2] Primary care management of benign prostatic hyperplasia
    Anderson, RJ
    HOSPITAL PRACTICE, 1998, 33 (03): : 11 - +
  • [3] Congenital adrenal hyperplasia: what primary care physicians need to know?
    Pinto, Maria Ines de Gusmao Ramos Marques
    Martnez, David Blanquez
    Ponce, Maria Hayon
    MEDICINA DE FAMILIA-SEMERGEN, 2023, 49 (06):
  • [4] Doxazosin for benign prostatic hyperplasia in primary care
    Guthrie, R
    CLINICAL THERAPEUTICS, 1997, 19 (06) : 1269 - 1277
  • [5] Paediatric hypertension for the primary care provider: What you need to know
    Saini, Priya
    Betcherman, Laura
    Radhakrishnan, Seetha
    Etoom, Yousef
    PAEDIATRICS & CHILD HEALTH, 2021, 26 (02) : 93 - 98
  • [6] Referral criteria for benign prostatic hyperplasia in primary care
    Maria Molero, Jose
    Perez Morales, David
    Brenes Bermudez, Francisco Jose
    Naval Pulido, Esperanza
    Fernandez-Pro, Antonio
    Antonio Martin, Juan
    Castineiras Fernandez, Jesus
    Cozar Olmo, Jose Manuel
    ATENCION PRIMARIA, 2010, 42 (01): : 36 - 46
  • [7] Referral criteria for benign prostatic hyperplasia in primary care
    Castineiras Fernandez, J.
    Cozar Olmo, J. M.
    Fernandez-Pro, A.
    Martin, J. A.
    Brenes Bermudez, F. J.
    Naval Pulido, E.
    Molero, J. M.
    Perez Morales, D.
    ACTAS UROLOGICAS ESPANOLAS, 2010, 34 (01): : 24 - 34
  • [8] Diagnosis and management of benign prostatic hyperplasia in primary care
    Tanguay, Simon
    Awde, Murray
    Brock, Gerald
    Casey, Richard
    Kozak, Joseph
    Lee, Jay
    Nickel, J. Curtis
    Saad, Fred
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2009, 3 (03): : S92 - S100
  • [9] What do we know about phytotherapy of benign prostatic hyperplasia?
    Allkanjari, Olta
    Vitalone, Annabella
    LIFE SCIENCES, 2015, 126 : 42 - 56
  • [10] Chronic Inflammatory Infiltrate and Benign Prostatic Hyperplasia: What Do We Know?
    Bartoletti, Riccardo
    EUROPEAN UROLOGY SUPPLEMENTS, 2013, 12 (05) : 99 - 102